Novartis Commits $100M to Startup With Tech That Brings Peptides to Undruggable Targets

February 19, 2026
, 9:50 pm

A VPN is an essential component of IT security, whether you’re just starting a business or are already up and running. Most business interactions and transactions happen online and VPN

Novartis’s alliance with Unnatural Products is pursuing next-generation peptide drugs for cardiovascular disease. The startup already has drug R&D alliances with BridgeBio Pharma, Merck, and Argenx.

The post Novartis Commits $100M to Startup With Tech That Brings Peptides to Undruggable Targets appeared first on MedCity News.

Leave a Replay

4 Health Tech Trends Startups Can’t Ignore, Per an Oak HC/FT Partner

Coral Care Raises $13M to Scale In-Home Pediatric Therapy

Headache Startup Slate Medicines Lands $130M to Bring Novel Migraine Drug Into the Clinic

Sign up for our Newsletter

HealthGility provides healthcare organizations with a solution for patient protected health information disclosure and confidentiality that reduces workloads and ensures the safe and secure sharing of sensitive data between different providers.

Novartis Commits $100M to Startup With Tech That Brings Peptides to Undruggable Targets

Leave a Replay

Related Posts

4 Health Tech Trends Startups Can’t Ignore, Per an Oak HC/FT Partner

Coral Care Raises $13M to Scale In-Home Pediatric Therapy

Headache Startup Slate Medicines Lands $130M to Bring Novel Migraine Drug Into the Clinic

Follow Us

Sign up for our Newsletter

Our Company

Resources

Connect

© All rights reserved

Contact Us